Eden Rahim, portfolio manager and options strategist at Next Edge Capital, joins BNN Bloomberg to discuss his top picks in biotech. M&As in the sector have picked up this year, and he believes the market has been mispricing biotech companies. His top picks were Biogen, Crispr Therapeutics and Exelixis.